DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc trimmed its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 1.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 274,500 shares of the medical device company's stock after selling 3,813 shares during the period. Ensign Peak Advisors Inc owned 0.07% of DexCom worth $21,348,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Private Trust Co. NA lifted its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares during the last quarter. Optiver Holding B.V. bought a new position in DexCom during the fourth quarter valued at $33,000. TD Private Client Wealth LLC lifted its position in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares during the last quarter. Larson Financial Group LLC lifted its holdings in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after acquiring an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC bought a new stake in shares of DexCom in the 4th quarter worth about $38,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on DXCM. Robert W. Baird lowered their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Morgan Stanley raised their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Canaccord Genuity Group raised their target price on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Finally, Cfra Research upgraded shares of DexCom to a "hold" rating in a report on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.11.

DexCom Stock Down 0.6%

NASDAQ DXCM traded down $0.48 during trading on Friday, reaching $85.19. 1,168,346 shares of the company's stock traded hands, compared to its average volume of 4,338,550. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm has a market cap of $33.40 billion, a price-to-earnings ratio of 59.65, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. The company's 50 day simple moving average is $71.70 and its two-hundred day simple moving average is $77.51. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $132.26.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same period in the previous year, the firm earned $0.32 EPS. The firm's quarterly revenue was up 12.5% on a year-over-year basis. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In related news, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the sale, the executive vice president now directly owns 105,602 shares in the company, valued at $7,432,268.76. This trade represents a 10.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares of the company's stock, valued at $26,183,401.02. This trade represents a 8.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,926 shares of company stock valued at $4,734,384 in the last 90 days. Insiders own 0.32% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.